NuPathe, Inc.

Industry

  • Medical Devices
    • Implantable Devices
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Transdermal
    • Specialty Pharmaceuticals
  • Biotechnology
See more in Biomedtracker

Latest on NuPathe, Inc.

Pink Sheet

US FDA's Search For Meaning: Interpretation Of Regulatory Language Can Inspire Conflict In Drug Reviews

 
• By Bridget Silverman

Translating statutory language into regulatory practice is a frequent challenge for FDA reviewers, who must apply vague terms like "substantial improvement" and "confirmatory evidence" to the sometime

Scrip

Teva Hits Pause On Business Development, Even As Some Deals Stumble

 
• By Jessica Merrill

Teva Pharmaceutical Industries Ltd. CEO Erez Vigodman said the company will focus on organic growth and step away from business development for the “foreseeable future” as it digests the $40.5bn acq

Pink Sheet

Zecuity Redesign Got Migraine Patch Through FDA, But Burning Continued

 
• By Brenda Sandburg

FDA thought burning and scarring effects with NuPathe Inc. 's migraine therapy Zecuity could be addressed with a redesign that added technology to ensure proper placement of the patch, but persis

Pink Sheet

Teva Zecuity's Safety: Burns Go From Non-Issue In Label To Product Puller

 
• By Brenda Sandburg

Nine months after launching its migraine treatment Zecuity (sumatriptan iontophoretic transdermal system), Teva Pharmaceutical Industries Ltd. has voluntarily suspended marketing of the patch fo